In ruminant tablet and bolus manufacturing, the critical variable is not active content but the behaviour of β-glucan and mannoprotein fractions under uniaxial compression. These polysaccharides deform plastically rather than by brittle fracture, so tablet hardness is strongly influenced by moisture and compression dwell time. On a rotary press equipped with 19.0 mm flat-faced punches and operated at 8–14 kN compression force, formulations containing 20–60 wt% dried yeast preparation, 40–80 wt% direct-compression diluent such as dibasic calcium phosphate dihydrate or microcrystalline cellulose, and 0.5–1.0 wt% magnesium stearate yield compacts with friability below 1.0% only when moisture content remains between 2.5 wt% and 5.5 wt%. Higher moisture produces sticking and picking on punch faces; lower moisture reduces tensile strength and increases capping at the precompression boundary. Preformulation should therefore include dynamic vapour sorption at 25 ± 1 °C and 40% RH, loss on drying per USP <731>, and particle size analysis by laser diffraction with dry dispersion at 0.5 bar. Disintegration time per USP <701> in 0.1 M hydrochloric acid at 39 ± 1 °C for rumen boluses generally remains below 30 min when compression force does not exceed 16 kN, creating a narrow processing window for large 25–50 g boluses intended for oral administration in cattle. The terminal dosage form is a hard bolus with assay for mannan oligosaccharides by high-performance anion-exchange chromatography with pulsed amperometric detection and uniformity of dosage units per USP <905>. Batch release also includes a microbial limits panel because yeast preparations may retain residual viable cells; if a non-viable claim is made, thermal kill validation must demonstrate absence of growth on Sabouraud dextrose agar after 48 h at 25 ± 2 °C.

Scale-up from laboratory to production rotary press requires monitoring of ejection force and tablet thickness during the first 15 min because yeast-containing compacts exhibit viscoelastic recovery after decompression. If ejection force exceeds 8 kN, blending time, precompression force, and granule moisture are adjusted in sequence. Aqueous film-coating of yeast-containing boluses with hydroxypropyl methylcellulose at 3–5 wt% weight gain is feasible only when core bed temperature remains below 38 °C; above this threshold, lipid-containing yeast surface residues cause orange-peel or cratering defects. The finished bolus package includes a desiccant canister and a heat-sealed aluminium pouch to maintain core moisture below 5.0 wt% through the labelled shelf life.

What Limits Sterile Filtration of Solubilized Yeast Fractions for Parenteral Use?

Parenteral veterinary products containing yeast-derived fractions are constrained by the behaviour of β-1,3-glucan aggregates in aqueous media. Intact yeast cell-wall particles are irregular and typically exceed 1.0 µm, so they are retained by 0.22 µm sterilizing-grade polyethersulfone or polyvinylidene fluoride membranes. Solubilized or colloidal fractions intended for intramuscular or subcutaneous injection require a two-step clarification train: a charged depth filter followed by a 0.45 µm prefilter and a 0.22 µm final filter. Filtration flux should be limited to 60–120 L/m²/h and transmembrane pressure kept below 1.4 bar because glucan gels compress into the filter matrix and reduce throughput. Depyrogenation is not reliably achieved by sterile filtration alone; tangential flow filtration through a 100 kDa regenerated cellulose membrane removes free endotoxin from soluble yeast fractions, but endotoxin adsorbed to beta-glucan particles may be masked from routine LAL detection unless a dispersing agent is used. Terminal sterilization at 121 °C for 15 min is generally unsuitable for particulate beta-glucan suspensions because the triple-helix conformation may dissociate and the particle-size distribution may shift above 2 µm, violating injectable particle size limits. Aseptic filling is therefore preferred. The table below summarizes release tests; published data for this specific configuration is limited, so the endotoxin limit must be derived from an in-house maximum tolerated dose study under veterinary parenteral safety guidelines rather than transferred from another product.

Because dosator-type capsule filling is sensitive to bulk density fluctuations, a yeast preparation intended for companion animal capsules is rarely filled without a prior densification step. The preparation may be wet-granulated with 1.0–2.0 wt% povidone K30 or precompacted into slugs at 4–8 kN and milled through an 0.8 mm screen. Final blends for size 0 or size 1 hard gelatin or hydroxypropyl methylcellulose capsules typically include 0.5–1.0 wt% colloidal silicon dioxide and 1.0–2.0 wt% sodium stearyl fumarate as a hydrophobic lubricant, with fill weight between 250 mg and 400 mg depending on the labelled yeast preparation content. In-process weight variation is controlled to ±5.0% of the target capsule weight, and filled capsules are metal checked and dedusted before packaging. Dissolution testing per USP <711> in 0.1 M hydrochloric acid with pepsin at 37 ± 0.5 °C should be developed for dogs or cats, but acceptance criteria are product-specific and cannot be transferred from human generic capsules. Published data for yeast preparation capsules is limited because no pharmacopoeial monograph exists for the raw material. The terminal product is a hard capsule containing either viable yeast cells standardized to colony-forming units per gram or inactivated yeast-derived mannan and glucan fractions, and the label must state the basis of standardization to prevent dosing errors in veterinary practice.

Stability of yeast-containing capsules in high-humidity climates is governed primarily by shell brittleness and moisture exchange. Gelatin capsules stored above 60% RH lose shell integrity, while hydroxypropyl methylcellulose capsules tolerate higher relative humidity but have greater oxygen permeability. To prevent moisture exchange between the yeast preparation and the shell, the blend is dried to below 5.0 wt% water and packaged in PVC/PVDC blisters with desiccant. Photodegradation of B vitamins in yeast-derived material is minimized by using opaque capsules or carbon black ionomer blister lidding. Terminal release includes dissolution, water activity, and microbial enumeration. Stability-indicating markers such as mannan content should be validated in-house because no external pharmacopoeial specification exists for the specific configuration.

When a Yeast Preparation Is Dispersed in Oral Electrolyte Solutions for Neonatal Calves

To prevent flocculation of yeast cell-wall particles in an oral drench, the preparation should be incorporated into warm water at 35–40 °C using a high-shear mixer at 1000–3000 rpm for 3–5 min. A typical drench formulation contains 5–15 g/L yeast preparation, 1.5–2.0 g/L sodium chloride, 3.0–5.0 g/L glucose monohydrate, and 0.3–0.5 g/L sodium citrate dihydrate; final osmolality is adjusted to 280–310 mOsm/kg. Foaming is controlled by adding 0.01 wt% polydimethylsiloxane antifoam or by deaeration under reduced pressure. The sedimentation ratio after 1 h should be at least 0.90; if not, wetting may be improved with 0.05 wt% lecithin or by one-pass homogenization at 50–100 bar. The terminal product is an oral powder for reconstitution, filled into foil-lined sachets under dry conditions. After mixing, unpreserved suspensions should be used within 24 h and stored at 2–8 °C if not consumed immediately.

In farm-scale administration, water hardness and pH affect dispersion performance. Water with total hardness above 200 mg/L calcium carbonate may reduce electrostatic repulsion between yeast particles, causing rapid sedimentation. In such water, a weak acidulant such as citric acid at 0.5–1.0 g/L restores dispersibility. Mixing should avoid prolonged high-shear recirculation because shear-induced fragmentation of yeast cell walls releases soluble intracellular markers but does not necessarily reduce biological activity. Any claim of oral bioavailability or immune support must be tied to a standardized marker compound, preferably β-glucan content by enzymatic assay, rather than gross dry matter intake.

In a top-spray fluid-bed process, the transition from a dusty yeast preparation into free-flowing granules depends on three interacting parameters: inlet air temperature, binder spray rate, and atomizing air pressure. Typical settings include inlet air temperature 55–65 °C, product temperature 32–38 °C, binder spray rate 8–12 g/min/kg, and atomizing air pressure 1.5–2.0 bar, using 2.0–3.0 wt% hypromellose E5 solution as binder. The granulation endpoint is monitored by impeller torque or real-time near-infrared moisture; target moisture before drying is 8.0–10.0 wt%, and final loss on drying is 3.0–5.0 wt%. Drying above 70 °C should be avoided because reducing sugars and free amino groups in yeast autolysate fractions undergo Maillard browning, reducing available lysine content and shifting granule colour. After drying, the product is sieved so that 60–80 wt% is retained between 0.250 mm and 0.850 mm, and fines below 0.075 mm are held under 10 wt%. Oversize granules are milled through a low-shear granulator fitted with a 1.0 mm screen. The terminal granules are immediately filled into aluminium/polyethylene composite sachets to maintain moisture below 5.5 wt%.

Granule hardness and dissolution are not independent in this system. Higher binder levels above 3.0 wt% reduce dust but also delay release in oral fluids; in adult cattle, a bolus-like granule that persists too long may pass through the rumen without complete disintegration. Fluid-bed granulation should therefore be validated by dissolution testing in water at 39 ± 1 °C with a paddle apparatus at 50 rpm, with release of water-soluble protein markers exceeding 80% within 30 min as a practical target. Packaging in single-dose sachets rather than multi-dose tubs reduces moisture uptake and caking in tropical field storage.

Premix Segregation and Carrier Selection in Mineral-Vitamin Blends

Yeast preparation incorporated into a mineral-vitamin premix is a low-inclusion component that segregates if its particle density and shape differ strongly from the carrier. Selection of a carrier such as ground corn cob fraction 0.5–1.0 mm or wheat middlings with bulk density 0.45–0.60 g/cm³ reduces segregation during pneumatic conveying and bag filling. In a horizontal ribbon mixer with a fill level of 60–70% and mixing time 10–15 min, uniformity of a tracer such as nicotinic acid or ferrous sulfate should achieve a coefficient of variation below 5.0% across 10 sampling points when assayed by HPLC. Yeast preparation is often added at 5–20 kg per tonne in the mineral-vitamin premix, corresponding to 0.5–2.0 wt%, and the premix is subsequently diluted into complete feed at 0.5–1.0 wt%. Iron, copper, and chloride sources are aggressive; they should be ordered as chelated minerals or placed in a separate micro-mix if β-glucan structural integrity is to be retained. Finished premix moisture is controlled below 6.0 wt% and water activity below 0.65 to prevent caking and loss of flow.

Feed additive authorization for yeast preparations in the European Union falls under Regulation (EC) No 1831/2003, with product-specific conditions published in implementing acts; in the United States, the application may fall under 21 CFR Part 558 when the preparation is used as a feed additive. Premix stability should follow VICH GL4. A critical scale-up failure in premix lines is the discharge sequence from the mixer: if the main gate is opened before the dribble gate has cleared the micro-mix, the yeast-rich fines fraction can segregate into the last 10% of discharge. This is controlled by sequencing valves and verifying uniformity in the first, middle, and last sacks of the batch.

For aqueous oral solutions, yeast autolysate fractions pose two simultaneous problems: pH-dependent precipitation and thermally induced loss of B vitamins. The yeast preparation is dissolved or dispersed in purified water at 40 ± 2 °C under continuous agitation for 15–20 min, then cooled to 20–25 °C before addition of a preservative system. Sodium benzoate at 0.1 wt% and potassium sorbate at 0.1 wt% are effective only below pH 5.5; benzoic acid precipitates at pH below 4.0, so a citrate buffer at 0.05 M is used to maintain pH 4.5–5.0. If a preservative-free concentrate is required, terminal sterilization at 110 °C for 30 min is preferable to 121 °C because the lower temperature reduces thermal degradation of thiamine and proteinaceous flavour fractions. The final solution is clarified through a 1.0 µm depth filter, filled into amber polypropylene or glass bottles, and checked for specific gravity between 1.010 and 1.035. The terminal dosage form is an oral liquid for swine, poultry, or cattle, with storage conditions defined by real-time and accelerated stability testing per VICH GL3 and photostability testing per VICH GL5.

Preservative efficacy is a central concern because yeast autolysate contains peptides and free amino acids that can inactivate some antimicrobial systems. Parabens are generally avoided in feline oral liquids due to species-specific sensitivity, while benzalkonium chloride is incompatible with high protein loads. The selected preservative system must be challenged by a compendial antimicrobial effectiveness test using Staphylococcus aureus, Pseudomonas aeruginosa, Candida albicans, and Aspergillus brasiliensis. If the product is administered through nipple drinkers or proportioner pumps, the solution should be screened through a 0.25 mm in-line strainer to remove any insoluble particle aggregates that could block delivery lines.